Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Texas Oncology- Sammons CC
mi
from
Dallas, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Texas Oncology- Sammons CC
mi
from
Dallas, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Texas Oncology- Denton South
mi
from
Denton, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Texas Oncology- Denton South
mi
from
Denton, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Texas Oncology-Central Austin Cancer Center
mi
from
Austin, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Texas Oncology-Central Austin Cancer Center
mi
from
Austin, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Texas Oncology - Baylor Charles A. Simmons Cancer Center
mi
from
Dallas, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Texas Oncology - Baylor Charles A. Simmons Cancer Center
mi
from
Dallas, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Texas Oncology - Sherman
mi
from
Sherman, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Texas Oncology - Sherman
mi
from
Sherman, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Texas Oncology-Tyler
mi
from
Tyler, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Texas Oncology-Tyler
mi
from
Tyler, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center
mi
from
Beaumont, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center
mi
from
Beaumont, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Texas Oncology-Waco
mi
from
Waco, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Texas Oncology-Waco
mi
from
Waco, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Texas Oncology Wichita Falls Texoma Cancer Center
mi
from
Wichita Falls, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Texas Oncology Wichita Falls Texoma Cancer Center
mi
from
Wichita Falls, TX
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Virginia Oncology Assoc.
mi
from
Norfolk, VA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Virginia Oncology Assoc.
mi
from
Norfolk, VA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Highline Medical Oncology
mi
from
Burien, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Highline Medical Oncology
mi
from
Burien, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Pudget Sound Cancer Center
mi
from
Edmonds, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Pudget Sound Cancer Center
mi
from
Edmonds, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Cancer Care Northwest
mi
from
Spokane, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Cancer Care Northwest
mi
from
Spokane, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Yakima Valley Memorial
mi
from
Yakima, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Yakima Valley Memorial
mi
from
Yakima, WA
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Lymph Fluid and Blood Collection for Identification of Novel Biomarkers
The Comparison of Lymph Fluid and Blood From Metastatic and Non-metastatic Invasive Breast Cancer Patients for Identification of Novel Biomarkers
Status: Archived
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Lymph Fluid and Blood Collection for Identification of Novel Biomarkers
The Comparison of Lymph Fluid and Blood From Metastatic and Non-metastatic Invasive Breast Cancer Patients for Identification of Novel Biomarkers
Status: Archived
Updated: 1/1/1970
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema
Intermittent, Gradient, Pneumatic Compression Plus Standard Compression for Hard-To-Heal Venous Ulcers in Subjects With Secondary Lymphedema and Chronic Venous Insufficiency
Status: Archived
Center for Curative & Palliative Wound Care Calvary Hospital
mi
from
New York, NY
Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema
Intermittent, Gradient, Pneumatic Compression Plus Standard Compression for Hard-To-Heal Venous Ulcers in Subjects With Secondary Lymphedema and Chronic Venous Insufficiency
Status: Archived
Updated: 1/1/1970
Center for Curative & Palliative Wound Care Calvary Hospital
mi
from
New York, NY
Fluorescent Dyes for Lymph Node Mapping
Near-Infrared Imaging of Fluorescent Dyes for Lymph Node Mapping
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Fluorescent Dyes for Lymph Node Mapping
Near-Infrared Imaging of Fluorescent Dyes for Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Fluorescent Dyes for Lymph Node Mapping
Near-Infrared Imaging of Fluorescent Dyes for Lymph Node Mapping
Status: Archived
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Fluorescent Dyes for Lymph Node Mapping
Near-Infrared Imaging of Fluorescent Dyes for Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderiblt University Medical Center
mi
from
Nashville, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderiblt University Medical Center
mi
from
Nashville, TN
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Gabrail Cancer Center Research LLC
mi
from
Canton, OH
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Updated: 1/1/1970
Gabrail Cancer Center Research LLC
mi
from
Canton, OH
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
A Study of MM-111 in Combination With (Herceptin) Trastuzumab in Patients With Advanced Her2 Positive Breast Cancer
MM-111-02-12-02: A Phase 1-2 Study of MM-111 in Combination With Herceptin (Trastuzumab) in Patients With Advanced, Refractory Her2 Positive Breast Cancer
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
UH-Richmond
mi
from
Richmond Heights, OH
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
Updated: 1/1/1970
UH-Richmond
mi
from
Richmond Heights, OH
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
Lake Shore Pediatrics
mi
from
Libertyville, IL
Breast-Conserving Surgery Followed by Radiation Therapy in Treating Patients With MRI-Detected Stage I or Stage II Breast Cancer
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Status: Archived
Updated: 1/1/1970
Lake Shore Pediatrics
mi
from
Libertyville, IL
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Providence, RI
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Providence, RI
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
University of Alabama - Burmingham
mi
from
Birmingham, AL
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
University of Alabama - Burmingham
mi
from
Birmingham, AL
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Moores Cancer Center
mi
from
La Jolla, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
Moores Cancer Center
mi
from
La Jolla, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
California Pacific Medical Center
mi
from
San Francisco, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
California Pacific Medical Center
mi
from
San Francisco, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Breast Care Specialists
mi
from
Columbus, OH
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
Breast Care Specialists
mi
from
Columbus, OH
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Ohio State University
mi
from
Columbus, OH
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
Status: Archived
Updated: 1/1/1970
Ohio State University
mi
from
Columbus, OH
Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice
Phase II Study of Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice
Status: Archived
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice
Phase II Study of Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice
Status: Archived
Updated: 1/1/1970
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ